Mechanisms of multistep carcinogenesis and carcinogen risk assessment. by Barrett, J C
EnvironmentalHealth Perspectives
Vol. 100, pp. 9-20, 1993
Mechanisms of Multistep Carcinogenesis
and Carcinogen RiskAssessment
by J. Carl Barrett
Manydifferent typesofchemicalexposures canincreasetheincidenceoftumors inanimalsandhumans, but usually
a long period oftimeisrequired before thecarcinogenic riskofanexposure is manisfested. Bothofthese observations
canbeexplained byamultistep/multigenemodelofcarcinogenesis. Inthismodel, anormalcellevolvesintoacancercell
as the resultofheritable changes in multiple, independent genes. The two-stage model ofinitiation andpromotion for
chemicalcarcinogenesis hasprovidedaparadigm bywhichchemicalscanactby qualitatively differentmechanisms, but
theprocess ofcarcinogenesis is nowrecognized as morecomplexthansimply initiationandprotion. Evenathree-stage
modelofinitiation, promotion, andprogression, whichcanbeoperationallydefined, isnotadequatetodescribethecar-
cinogenic process. Thenumberofgenesalteredinacancercellcomparedtoanormalcell isnotknown;recentevidence
suggeststhat3-10geneticeventsareinvolvedincommonadult magancesin humans. Tw distinctclassesofgenes, proto-
oncogenes andtumor-suppressorgenes, areinvlvedinthecancerprocess. Multipleoncogenesmaybeactiaedinatumnor,
while multiple tumor-suppressor genes may be inactivated. Identification ofthe genes involved in carcinogenesis and
elucidationofthemechanismsoftheiractivationorinactivationallowsabetterundersandingofhowchemicalcarcinogens
influence the process of neoplastic evolution. The findings of multiple genetic changes (including point mutations,
chromosomal translocations, deletions, gene amplification, and numerical chromosome changes) in activated proto-
oncogenesandinactivatedtumor-suppressorgenesprovideexperimentalsupportforBoveri'ssomaticmutationtheory
ofcarcinogenesis. Inadditiontomutagenic mechanisms, chemicalsmay heritably altercellsbyepigeneticmechanisms
andenhancetheclonalexpansionofalteredcells. Mostchemicalcarcinogensoperateviaacombinationofmechanisms,
andeventheirprimary mechanismofactionmayvarydependingonthetargettissues. Theclassificationofchemicalsby
mechanismofactionorbynongenotoxic orgenotoxicactivity hascertaininherent difficulties because noclassification
ofchemicals isexhaustive or definitive.
Carcinogenesis Is aMultistep Process
Cancer remains a major chronic health problem associated
withtoxicological substances. Thelonglatency periodofcancer
induction (years in rodents and decades in humans) is a major
problem in the evaluation of toxicological hazards and risk
assessment. We understand, at least in part, the underlying
reasons forthetimerequirement ofcancerformation. It is now
clearthat for anormal cell toevolve into a cancercell, multiple
heritablechanges withinthecell arerequired, i.e., carcinogene-
sis is amultistep processinvolvingmultiple genes. Several lines
ofevidence support theconclusion thatchemicalcarcinogenesis
is amultistep process. These arelistedinTable 1 anddiscussed
in detail elsewhere (1).
One ofthe underlying premises ofmost multistep models of
carcinogenesis is that genetic and/or epigenetic alterations of
multiple, independent genes areinvolved. Althoughthe process
ofchemical carcinogenesis is often separated operationally in-
tothree stages, i.e., initiation, promotion, andprogression (2),
the number ofgenetic changes involved in each ofthese opera-
tionally defined stages has not yet been determined.
Initiation involves the inductionofan irreversibly altered cell
and is frequently equated with a mutational event. This con-
Laboratory ofMolecularCarcinogenesis, National InstituteofEnvironmen-
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Table 1. Evidence for multistage modelsofcarcinogenesis.a
Histopathological observationsoftumors reveal multiplestagesoftumorprogres-
sion such asdysplasia and carcinoma in situ.
Two-stagemodelofchemical carcinogenesis inmouse skin showsthatdifferent
chemicals affect qualitatively different stages inthe carcinogenic process.
Individuals withgenetic traits manifested by anearly occurrenceofcancer (e.g.,
familial retinoblastomas, adenomatosisofthecolonandrectum) suggestthat
onestep inthecarcinogenic processcanbeagermlinemutation, butadditional
somatic events are requiredforneoplastic development.
Mathematical modelsbasedonage-specifictumorincidencecurvesareconsistent
with 3-7 independent hits required fortumors.
Cellculturestudieswithchemicalcarcinogens revealthatdifferentphenotypic
properties ofatumor cell areacquired by a progressive process.
Cellculturestudies withviral andtumor-derivedoncogenesshowthatneoplastic
conversionofnormal cellsgenerallyrequiresmultiplecooperatingoncogenes.
In contrast, certain preneoplastic (immortal) cells are neoplastically trans-
formed by a singleoncogene.
Transgenic micethatcarry activatedprotooncogenes intheirgermlinedevelop
focaltumors, whichareapparently monoclonal inorigin, suggestingthatad-
ditional somatic events are required for full malignantprogression.
aSeeBarrett (12) for a more complete discussion and references.
clusion is supportedby the findings ofmutational activation of
ras proto-oncogenes in rat mammary carcinomas, mouse skin
papilomas, and mousehepatomas (3-7). Themechanismsofin-
itiationmayvary, however, indifferenttissues orwithdifferent
initiators inthe sametissue(8). Promotionistheexperimentally
definedprocessbywhichtheinitiatedcellclonallyexpandsintoJ. C. R4RRE7T
avisible tumor, oftenabenign lesion suchasapapilloma. This
processundoubtedlyinvolvesatleastsomeepigenetic factorsthat
selectively influencetheproliferationoftheinitiatedcell. Wheth-
ergenetic mechanisms arealso involved intumorpromotion is
unclear. The end products of tumor promotion are generally
benign lesions or foci ofpreneoplastic cells. These cells must
undergooneormoreadditionalheritablechangesduringthepro-
gression to a malignant neoplasm. The progression ofbenign
tumors tomalignantcancers isaphaseincarcinogenesis clear-
ly distinct from promotion (9,10).
Inthepastdecade, therehavebeentremendousadvances inour
understandingofthetargetgenes incarcinogenesis (11,12). Two
classesofgenes, proto-oncogenesandtumor-suppressor genes,
are involvedintheevolutionofmost, ifnotall, cancers(Table2).
Proto-oncogenes, when activated by mutational mechanisms,
result in positive proliferative signals for tumors. Tumor-sup-
pressor genes, in contrast, blocktheneoplastic growth ofcells
by undefined mechanisms andtherefore mustbeinactivated or
lost in tumorcells (13). In most common humantumors (e.g.,
lung, colon, and breast) multiple tumor-suppressor genes are
frequently affected, indicatingthatmalignantgrowth is subject
to several levels ofnegative control (12,14,15).
Thenumberofgenes involvedinneoplasticdevelopmentisnot
knownwithcertainty. Mostcolorectalcancershavethreeormore
altered genes (16,17), and estimates ofas many as 10 or more
mutational changeshavebeenproposedtooccurinadulthuman
cancers (13). These findings areconsistentwithmultihitmodels
developedonthebasisofspecific incidence ratesofcancers in-
creasingexponentially withthefifthtoseventhpowerofage(18).
Analysis of multistep carcinogenesis at the molecular level,
therefore, indicates that the process ofneoplastic evolution is
significantly more complicated thanthe relatively simple two-
stage (initiation and promotion) model of carcinogenesis or
Table2. Two classesofgenes involved incarcinogenesis.
Proto-oncogenes Tumor-suppressor genes
Involved in cellular growth and Function unknown butpossibly in-
differentiation volved in cellulargrowth and dif-
ferentiation (negative regulators of
cell growth?)
Family ofgenes exists Family ofgenes exists
Activated (quantitatively or Inactivated or lost in cancers
qualitatively) in cancers
Activation by point mutation, Inactivation by chromosome loss,
chromosometranslocation, or chromosome deletion, point muta-
gene amplification tion, somatic recombination of
gene conversion
Little evidence for involvement in Clear evidence for involvement in
hereditary cancers hereditary and nonhereditary
cancers
Chromosome: 5q 12p
evenathree-stage modelofinitiation, promotion, andprogres-
sion. Asanexample, themodeldescribedby Vogelstein andco-
workers forcolorectal cancers (Fig. 1) shows that multiple ge-
netic changes mustoccurafterthepromotion orclonal growth
oftheinitiatedcells (16,17). Thus, theprogressionphaseofcar-
cinogenesis representsmultiplestagesatwhichchemicalsmight
influence theneoplastic process (19).
Therearethreegeneralmechanismsbywhichasubstancecan
influencethemultistep, carcinogenic process (Table3). A sub-
stance can induce a heritable alteration in one or more critical
genes inthemultistepprocessbyoneoftwomechanisms. This
heritable change may haveeitheragenetic orepigenetic basis.
Although considerable insight into the mechanisms ofgenetic
changesby chemicals exists, little isknown aboutthe mechan-
isms of carcinogen-induced epigenetic, heritable changes. A
thirdmechanismby which a substance can influence multistep
carcinogenesis is the facilitation ofclonal expansion ofan in-
itiatedorintermediatecell, whichincreasestheprobabilityofad-
ditional, spontaneous (mutationalorepigenetic)heritablechang-
es.
Mutagenesis asa Mechanism of
Carcinogenesis
Theoriginofthesomaticmutationtheoryofcarcinogenesis is
generallycreditedtoTheodorBoveri, whoin 1914publishedhis
book(20)ZurFragederEntstehungMalignerTumoren[Onthe
Problem ofthe Origin ofMalignant Tumors]. The English
translation ofthisbookbyhis wife, MarcellaBoveri, was pub-
lished in 1929. Boveri's hypothesis on the origin ofmalignant
tumors wasextraordinarily comprehensive and included many
predictions, whichsubsequently havebeenproventrue. Forthese
reasons, Boveri is generally acknowledged as the father ofthe
somatic mutation theory ofcarcinogenesis. There is now con-
siderableevidenceto supportthistheory, asdiscussedelsewhere
(21).
Genetic changes can be classified as either gene mutations,
chromosome rearrangements, gene amplification, or aneu-
ploidy. Therearenowclearexamplesofeachofthesemutational
changes indifferenttumors(Table4), whichprovidecritical sup-
port for the somatic mutation theory ofcarcinogenesis. Point
mutationshavebeenobservedtoactivate, proto-oncogenesand
to inactivate tumor-suppressor genes incertain cancers. Chro-
mosomerearrangementsofoncogenesarealsowelldocumented.
Geneamplification as well as numerical chromosomechanges
areimportantinanumberofdifferentcancers (21). Therefore,
chemicalsthatinduceanyoneofthesefourdistincttypesofgen-
etic events couldheritably alter acritical targetgene necessary
18q 17p
Ateation: MUTATION/LOSS MUTATION MUTATION/LOSS MUTATION/LOSS
Gen: APC/MCC K-RAS DCC pS3
FIGURE 1. A model forcolorectal cancer based on the workofVogelstein andcolleagues (16).
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Examples
Point mutation (G-T) in codon 12 of
the c-Ha-ras gene in EJ/T24 blad-
der carcinoma
Point mutation (A-G) in the splice
acceptor sequenceofexon 21 in the
retinoblastoma gene ofJ82 bladder
carcinoma cells
Philadelphia translocation t(9;22) in
chronic myelogenous leukemia,
t(8;14) in Burkitt's lymphoma
N-myc gene in neuroblastomas, c-
myc gene in lung carcinomas, neu
gene in mammary carcinomas
+12 in chronic lymphocytic
leukemia, +8 in acute nonlym-
phocytic leukemia, blast phase of
chronic myelogenous leukemia,
+15 in murine T-cell leukemias,
-22 in meningiomas, -15 in
Syrian hamster tumors induced by
transfection ofv-Ha-ras and v-mvc
forneoplasticdevelopment. Theseobservations supportthe use
ofmutagenicity assays intheevaluationofcarcinogenic risksof
chemicals to humans.
The mechanisms of carcinogen-induced activation of on-
cogenes havebeenelucidated, and theimplicationsofthese fin-
dings are highly important for risk assessment of chemicals,
which can be illustrated by three examples: a) Carcinogen-
induced point mutations, resulting in activation of a ras on-
cogene, have been demonstrated in carcinogenesis ofskin (4),
mammary gland (5), andliver(6,7). Inthesemodel systems, the
data support the conclusion that these point mutations are the
critical changes in the initiation ofthiese tumors. Thesefindings
provide experimental evidence for using the linear dose-
response curves observed inmutagenesis studies forcarcinogen
risk assessment in the absence of pharmacokinetic and other
data. b) Elucidation of oncogene activation by other genetic
changes (Table4) such as chromosomerearrangementsand gene
amplification provides a theoretical framework for the use of
these endpoints in risk assessment. c) Theobservationsthat nor-
mal cells are not neoplastically transformedby a single oncogene
but rather require two or morecooperating oncogenes and inac-
tivation ofmultipletumor-suppressorgenes support amultistep
or multihit model ofcarcinogenesis(22-24) andhavesignificant
implications for risk assessmentofchemicals. Because at least
multiple mutations must occur for a tumorcell toariseandthese
mutations may occurby different genetic mechanisms, it is not
surprising that asingletoxicological endpoint, such as carcino-
gen-DNAadducts, doesnotalways correlate withcarcinogenic
potency ofchemicals.
Tumor Promotion and Tumor
Progression
Themultistep/multigenemodelofcarcinogenesisprovidesin-
sightsinto many importantfeaturesofcancerdevelopmentand
carcinogen risk assessment. Thenecessity for amalignantcell
toacquiremultiple, heritablealterations atindependentgenetic
loci explains, atleastin part, thelonglatency periodfor cancer.
This model also explains how noncarcinogenic substances can
influencethecarcinogenic process. Chemicalsthatinfluencethe
clonalproliferationofinitiated orotherintermediatecells inthe
neoplastic process may increasetheriskofcancerdevelopment
in exposed populations. Conversely, chemicals that are highly
mutagenic but do not induce cell proliferation may be noncar-
cinogenic. Thecarcinogenicity ofthesechemicals will depend,
however, onthe stateofproliferationofthe targettissue. For ex-
ample, polycyclic hydrocarbons, aromatic amines, and nitro-
soamines arehighlycarcinogenic intheliversofneonatalmice,
butthe same exposures toadultmice arenoncarcinogenic inthe
liver due to a lack ofcellproliferation (25).
Theendproductoftumorpromotion isgenerally abenign le-
sion orfociofpreneoplasticcells. Thesecells mustundergo one
or more additional heritablechangesduring theprogression to
a malignant neoplasm. The progression of benign tumors to
malignant cancers is a phase in carcinogenesis clearly distinct
from promotion. This conclusion is supported by a number of
observations. Malignanttumors aredistinctfrombenign tumors
orotherpreneoplastic lesions intermsoftheirhistopathological
characteristicsofcellularmorphology, invasiveness, growth, and
differentiation. Thestagesofpromotionandprogression canalso
bedistinguished on thebasis ofdifferential responses tocertain
chemical treatments. In initiation-promotion experiments on
mouseskin, theincidenceofcarcinomas is notnecessarily pro-
portional tothenumberofpapillomas (26-32). Telocidin, anin-
dolealkaloid, induces morecarcinomas, butfewerpapillomas,
than the phorbol ester promoter 12-0-tetradecanyolphorbol-
13-acetate (TPA) on7,12-dimethylbenz[a]anthracene(DMBA)-
initiated mouse skin (28). Mezerein is a weak promoter of
epidermal papillomas inSENCARmice, but ityields a similar
numberofcarcinomas asthe potent promoter TPA (31). Like-
wise, the free-radical-generating chemical benzoyl peroxide is
only moderately active as a promoter ofpapillomas but is far
moreactivethanTPA ininducingmalignant tumors(32). Final-
ly, theanti-inflammatory steroidfluocinoloneacetonide inhibits
papillomas initiatedby DMBAandpromotedby7-bromomethyl-
benz[a]anthracene withoutaffectingthecarcinomaincidence in
treated mice (30). These studiesclearly indicatethatthe induc-
tion ofcarcinomas isonly in partdeterminedby the number of
the benign papillomas.
Tumor promoters, although effective in producing multiple
benign tumors orpreneoplastic foci, are notparticularly effec-
tive ininfluencingtheprogressionoftheselesionstomalignant
neoplasms in manyexperimentalmodels (10,34). Forexample,
in the mouse skin model, phorbol ester tumor promoters in-
fluence malignant progression by increasing the number of
precursor lesions (i.e., papillomas), butdo notdirectly induce
thetransitionofpapillomastocarcinomas(10,32). Treatmentof
benign tumors with alkylating and other mutagenic agents in-
creases the frequency andrateofmalignantconversion (19,32).
The promoter TPA is ineffective in enhancing malignant pro-
Table3. Mechanisms by which a substance can influence
multistep carcinogenesis.
By inducing heritable mutation in a critical gene
By inducing heritable, epigenetic change in a critical gene
By increasing clonal expansionofacell with aheritable alteration in a critical
gene, allowing for increased probability ofadditional events
Table4. Examples ofmolecular, genetic, and cytogenetic
changes in tumors.
Type ofgenetic change
Gene mutation
Chromosome rearrangement
Gene amplification
Aneuploidy
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gression, but other promoters (e.g., benzoyl peroxide and
telocidin) may effect both promotion and progression (28,33).
These observations caution against using premalignant lesions
alone for carcinogen risk assessment of tumor promoters
because in certain cases the incidence of benign tumor may
greatly overestimate or underestimate the risk for malignant
cancers.
The evolution of malignant tumors from benign lesions
involves theacquisitionofone or morequalitativechanges inthe
precursor cells. In fact, progression probably involves mul-
tiple, heritable changes. In mouse skin, papillomas display no
histopathological evidenceofdysplasiaafter 10weeksoftumor
promotion with phorbol esters (35,36); however, at later times
(20-40 weeks of promotion), the papillomas show evidence
ofmoderate to severe dysplasia and, concomitantly, aneuploid
tumor cells are detectable. These phenotypic changes are also
observed in the carcinomas that arise from these papillomas
(35). In chemically induced rat hepatocarcinogenesis, mul-
tiple events arepostulated tobe involved intheprogressionphase
(37,38). In other tissues, morphological evidence for multi-
ple steps in the progression of dysplastic lesions to carcino-
mas in situ and to malignant carcinomas is well established
(39).
From epidemiological studies, some human carcinogens have
been shown to affect predominantly late stages in the car-
cinogenic process (18). Thisdoes notnecessarily imply thatsuch
chemicals operate in a manner similar to tumor promoters in
two-stage experimental models. A given chemical may affect
events in the progression phase of carcinogenesis, which, as
described above, are notaffected byclassical promoters such as
the phorbol esters (19).
Arsenic is anexampleofachemical that may actprimarily as
a tumor progressor, i.e., achemical thataffects theprogression
stageofcarcinogenesis. Arsenic is awell-establishedcarcinogen
in humans (40), butthereislittleevidenceforitscarcinogenicity
inanimals (41-43). It is inactive as an initiator ortumorpromoter
in a two-stage model of epidermal carcinogenesis in mice
(44,45). Brown and Chu (46) have proposed that arsenic ex-
posure affects a late stage in the carcinogenic process based on
exposure effects in humans. These authors have further postu-
latedthatthehuman data are inconsistentwiththehypothesisthat
arsenic acts during the promotion phaseofthecarcinogenic pro-
cess. One of the purported hallmarks of tumor promotion is
reversibility (47). However, epidemiological studies ofhuman
cancers caused by arsenic exposure fail to show reversibility of
the excess lung cancer mortality after exposure ceases (46).
Based ontheseobservations, we haveproposedthatarsenic acts
specifically intheprogressionphaseofcarcinogenesis (48). This
hypothesis is supported by ourobservationthatarsenic is anef-
fective inducerofgeneamplification (48)and wouldexplainwhy
arsenic is ineffective as acompletecarcinogen, initiator, ortumor
promoter. Oncogene amplification has been shown in some
tumors to correlate with the degree of neoplastic progression
(49-52) and arsenic-induced oncogene amplification may ex-
plain theobserved increaseoftumors at alate stage inhuman car-
cinogenesis. These findings emphasize the importance of con-
sidering all the steps in the multistep process ofcarcinogenesis.
Carcinogen evaluation based only on theprinciples ofinitiation
andpromotion may notaccurately predict the hazards ofhuman
carcinogens.
Mechanisms of Known Human
Carcinogens
The genetic toxicology of known human carcinogens iden-
tified by the International Agency for Research on Cancer
(IARC) hasrecently beenreviewed (53-55). Theconclusion of
these reviews is that most, but not all, human carcinogens are
Table 5. Mutagenicity ofInternational Agency for Research on Cancer
group1 humancarcinogens inbacteria and rodent bone marrow tests.'
Salmonella Rodent bone-marrow
Carcinogens mutagenicity cytogenetic effects
Organic compounds
Aflatoxins + +
4-Aminobiphenyl + +
Analgesics containing phenacetin + +
Azathioprine + +
Benzene - +
Benzidine + +
Betel quid and tobacco + +
bis(Chloromethyl)ether and + I
chloromethyl ether
Chlorambucil + +
Chlornaphazine + +
Cyclophosphamide + +
Melphalan + +
Methyl-CCNU + +
MOPP (andothercombined + +
therapies)
Mustard gas + +
Myleran + +
2-Naphthylamine + +
Tobacco, smokeless + +
Tobacco smoke + ND
Tresulphan + +
Vinyl chloride + +
Soots, tars, and oils
Coal-tar pitches + ND
Coal tars + ND
Mineral oils, untreated and mildly + ND
treated
Shake oils ? ?
Soots + ND
Hormonesbc
Diethylstilbestrol - +
Estrogen replacement therapy ND ND
Estrogens, nonsteroidal ND ND
Estrogens, steroidal ND ND
Oral contraceptives, combined ND ND
Oral contraceptives, sequential ND ND
Metalsb
Arsenic compounds - +
Chromium compounds + +
(hexavalent)
Nickel and nickel compounds - ND
Fibers
Asbestos - ND
Erionite ND ND
Talc-containing asbestiform fibers
Other
8-Methoxypsoralen + UV + ND
Abbreviations: CCNU, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitro-
sourea; MOPP, nitrogen mustard vincristine procarbazine and prednisone.
'I, conclusive; ND, nodata; +, positive response; -, negative response; ?,
responses differamong different membersofthis group (54).
bThedetermination ofcarcinogenicity appliestothegroupsofchemicals as a
whole and not necessarily toall chemicals within each group.
cLimited test results are available, but the group of agents that includes
estrogens, progestins, andtheircombinationstypicallygive negative results in
genetic toxicity studies (54).
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active in a variety ofgenetic toxicology tests. Table 5 is a sum-
mary taken from Shelby and Zeiger (54) ofthe mutagenicity of
known human carcinogens subdivided into different chemical
groups. Thefirst group isthe organic compounds, thevastma-
jority ofwhich are active in inducing Salmonella mutagenesis
andchromosomeaberrations ormicronuclei intherodentbone
marrowtestsin vivo. Forchemicals notadequatelytested, their
predicted activity was based on structural alerts (56).
The soots, tars, and oils are also generally active in the Sal-
monella assay, and whentested they areactive inother systems,
although in many casesthese studieshavenotbeendone. Some
ofthecarcinogenic metalsarenotactiveintheSalmonellaassay
but show activity inavariety ofothertestsystems, inparticular,
clastogenicity assays. This findingemphasizes thenecessity of
notlimiting testing ofmutagenicity togenemutation assaysbut
rather of examining the full spectrum of possible mutational
events.
Twoclassesofchemicalsthataregenerally inactive inassays
for mutagenicity are the mineral fibers and the hormones.
Therefore, it is worthwhile to discuss in more detail the mech-
anisms ofactionofthesetwo classesofknown human carcino-
gens.
Asbestos Carcinogenicity
Asbestos is clearly carcinogenic in a wide variety ofanimal
and human studies (57). Asbestos andothermineral fibers are
generally described as nongenotoxic carcinogens becausethey
are inactive in a variety of short-term tests, particularly gene
mutation tests (58). It has been proposed that asbestos must
operate as a tumor promoter, not as an initiator, and there are
several linesofevidencethat areconsistentwiththishypothesis
(58). There is a synergistic interaction between asbestos ex-
posure and smoking fortheriskoflungcancer inhumans (59).
Ithasbeen suggested inthesecasesthatsmoking istheinitiator
and asbestos is apromoter. Thisfindingcouldbeexplainedjust
aswell byassumingthatasbestos istheinitiatorandsmoking is
thepromoterorthatsmoking istheinitiatorwithsomeunknown
promotional stimulusandthatasbestosactsinthelaterphasesof
progression by nonpromotional mechanisms. Thereisalsoaco-
carcinogenic effectofasbestos andvariouspolyaromatic hydro-
carbons, and this might be involved in the synergism between
smoking and asbestos. Topping and Nettesheim (60) demon-
strated thatasbestosenhances DMBA-inducedcarcinomas inthe
rattracheal transplant model. In thismodel, asbestos alone in-
duced a low incidence of tumors; however, there was a clear
enhancementofDMBA-induced cancers by asbestos. Whether
this is strictly a promotional effect of asbestos remains to be
elucidated. Finally, thereisanumberofobservationsindicating
thatasbestosinducescellularandbiochemical changes, suchas
hyperplasia, metaplasia, DNAsynthesis, andstimulationofox-
ygen free-radicals that are typical ofknown tumor promoters
(61,62). By analogy to other promoters, therefore, it has been
suggested that asbestos is operating through promotional
mechanisms.
On the other hand, there is also evidence that asbestos can
operate as aninitiating agent. Asbestos isacompletecarcinogen
in a wide variety of animal models by multiple routes of ad-
ministration (57,63-65). Epidemiological datainhumans suggest
that asbestos acts at anearly stage inmesothelioma formation,
whichwouldbeconsistentwithaninitiationeffect(65). Twoad-
ditional lines of evidence suggest conceptually that asbestos
mighthaveinitiating potential. Althoughasbestosisinactiveas
a gene mutagen, it induces chromosomal mutations, both
aneuploidyandaberrations, inawidevarietyofmammaliancells
including mesothelial cells inculture(66). Asbestostreatment
ofeitherhumanorrodentcellsalsoinduces celltransformation,
leading to neoplastic progression (58,66).
Asbestos induces morphological and neoplastic transforma-
tionofSyrianhamsterembryocells (67). Fiber-induced trans-
formation in this in vitro model parallels in vivo induction of
mesotheliomas inratsinthatcelltransformation isdependenton
fiberdimension. Celltransformationismoreeffectively induced
by long, thin fibers than by short, thick fibers. Reducing fiber
length fromapproximately 15p4mto2Amhas adramatic effect
onreducingactivity, andfibers shorterthan 1 pmareessential-
ly inactive (67).
Howcanasbestosleadtoheritable, neoplasticalterationsofex-
posedcells?Themechanismproposed(58,66)isthattheasbestos
fibers are phagocytized by the cells and accumulate inside the
cellsaroundtheperinuclearregion. Whenthesecellsattemptto
undergodivision, thereisphysical interferencebythefibers with
thenormalprocessofmitoticchromosome segregation, leading
toanaphaseabnormalities, such as chromosome losses, gains,
and aberrations (68). Agoodcorrelation betweenthe abilities
ofdifferentfiberstoinducecelltransformationandchromosomal
changeshasbeenreported(68). Thesechanges arerandom, but
the transformed cells have nonrandom chromosomal changes
associatedwiththeearlystagesoftransformation. Forexample,
trisomy ofchromosome 11 isobservedinthemajorityofhamster
cells transformed by asbestos (70). Immortalization (escape
fromcellularsenescence) isanearly eventinasbestos-induced
transformationwhichinvolveslossofanormalgenerequiredfor
senescence. By reintroducing human chromosomes into these
transformedcells, thenormal processofcellular senescence is
restored. Thegeneinvolved in senescence has beenmapped to
aregiononthelongarmofhumanchromosome 1 (71). Human
mesotheliomas arehighlyaneuploidand show awidevarietyof
chromosome changes, but several nonrandom structural and
numerical changes havebeen identified, including changes on
chromosome 1 (62). Becausethereisclearevidencefornonran-
dom chromosomal changes in mesotheliomas and because
asbestos fibers inculturecan inducechromosomal alterations,
it is reasonable to assumethatthis mechanism plays some role
inthegenesisofasbestos-related cancers. This is notlikely the
solemechanismofactionforasbestos. Infact, thepromotional
mechanismsmentionedearlierareprobablyquiteimportantas
well. The target cells for mesotheliomas are generally non-
proliferative. In order for chromosomal changes induced by
asbestostooccur, normalmesothelialcellsneedtobestimulated
toproliferate(fl). Boththeinductionofcellproliferation as well
asthesubsequentchromosomal changesareprobably involved
in the asbestos carcinogenicity.
Hormonal Carcinogenicity
Hormones represent another class ofimportant human car-
cinogens. As reviewed recently by Preston-Martin et al. (73),
estrogenic hormonesplayamajorroleintherelativeriskfordif-
ferent cancers in women, includingendometrium, breast, and
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ovariancancer. Thenaturalestrogen 17,-estradiolincreasesthe
incidences ofmammary, pituitary, uterine, cervical, vaginal, and
lymphoidtumors,andinterstitial-celltumorsofthetestesinmice;
italsoincreasestheincidencesofmammaryandpituitarytumors
inratsandrenaltumorsinhamsters(74). Perhapsthebest-studied
humancarcinogen intermsofmechanismofactionisthesynthetic
hormonediethylstilbestrol (DES). WhenDESwasgiventhera-
peuticallytowomenduringpregnancy,theiroffspringhadahigher
incidenceofclear-celladenocarcinoma(75). Thischemicalalso
induces cancer inawidevariety ofanimal models. Diethylstil-
bestrol increasestheincidencesofmammarytumors,lymphoid
tumors, interstitial-celltumorsofthetestes,cervicaltumors,and
vaginaltumorsinmice;pituitary, mammary,andbladdertumors
in rats; and renal tumors in hamsters (74). Studies on the
mechanismofactionofDESindifferentmodelsleadtothecon-
clusion that not one single mechanism but rather multiple
mechanisms areinvolvedintheactionofthishumancarcinogen.
Several possible mechanisms by which hormones may in-
fluencecancerdevelopmentaregiveninTable6. Ithasbeenpro-
posedthatestrogensarecarcinogenic dueprimarilytotheirabili-
ty to stimulate cell proliferation. Thehormonal dependence of
transplantable tumors isconsistentwiththisproposedmechan-
ismofaction. This hypothesis is also supportedby experimen-
tal observations of tumor-promoting effects of estrogens on
carcinogen-initiatedmammarycancers,livercancers,andvaginal
tumors(74,76). Analysesoftheinfluenceofhormonalfactorson
humanbreastcancersalsoindicateaneffectonalatestageinthe
carcinogenicprocess, consistentwithapromotionaleffect(18).
Therefore, thereisevidencefromseveralsystemsinsupportofthe
hypothesis thatestrogensareepigenetic carcinogens acting via
a promoting effect related to stimulation of proliferation of
estrogen-responsive cells. In addition, DES heritably repro-
grams developmental processes and results inmarkedchanges
in the expression of the differentiation phenotype of cells in
animals following exposure to DESduringcriticaldevelopmen-
talperiods(77,78). ThemechanismsbywhichDESinducessuch
striking changes in the entire endometrium are unknown.
Despite the convincing evidence that estrogens have an
epigenetic effect oncarcinogenesis, thereareobservationsthat
indicatethatestrogens canalso induceheritablealterationsim-
portant in neoplastic development. Diethylstilbestrol induces
tumors inhumansandexperimental animalsfollowingsingleor
short-term prenatal exposure (74,79). The offspring oftreated
animals haveincreased tumorincidences, eventhoughthey are
notexposedtofurthertreatment. Newboldetal. (79)haveshown
thatDES treatmentofneonatal micefromdays I to5afterbirth,
atimeperiodthatcorresponds tolateprenatal humandevelop-
ment, results in a high incidence (90%) ofuterine adenocar-
cinoma at 18 months ofage. Inthis model, tumors are induced
by brieftreatments or even a single injection ofDES.
Thereisalsoevidencethatestrogenicactivity isnotsufficient
toexplainthecarcinogenicactivity in vivoofestrogensincertain
target tissues. In the neonatal mouse, few ofthe target uterine
Table6. Mechanisms ofhormonal carcinogenesis.
Hormonal stimulation ofcell proliferation
Heritable reprogramming ofcellulardifferentiation
Induction ofgenetic changes intarget cells eitherby:
Induction ofnondisjunction andaneuploidy via microtubulealterations or
Induction ofmutagens following activation toDNA reactive intermediates
epithelialcellsarepositive fortheestrogen receptoratthetime
oftreatment; in contrast, similar treatments ofadult animals,
whenallthecellsareestrogen-receptor positive, doesnotresult
inDES-induceduterinecancers. Inthehamsterkidney model,
renaltumorsareinducedbyavarietyofestrogens,andthetumors
that form areestrogendependent, indicating an important epi-
geneticmechanism inthegenesisandmaintenanceofthistumor
(76). However, not all estrogens are active in inducing these
tumors. TumorsareinducedbybothDESand 17,-estradiol (E2),
but ethinyl estradiol has only weak carcinogenic activity even
though it competes equally well with DES and E2 forestrogen
receptorsandhasactivity similartocarcinogenic estrogensinin-
ducing renal progesterone receptor and serum prolactin levels
(80). Similarly, 2-fluorestradiol doesnotinducerenalclear-cell
carcinomas in hamsters despite its estrogenic potency (81).
Furtherevidenceforadirectestrogen-inducedeffectontarget
cells was provided by studies of neoplastic transformation of
Syrianhamsterembryo (SHE)cellsbyDES, E2, andotherestro-
gens. DESandE2inducemorphological andneoplastictransfor-
mationofSHEcellsthatisindistinguishable fromthatinduced
byotherchemical carcinogens suchasbenzo[a]pyrene (78,82).
InanattempttounderstandDES-inducedcelltransformation, the
abilityofDEStoinduceavarietyofgeneticchangesinSHEcells
wasexamined. TreatmentofthesecellswithDESaloneinduces
celltransformationwithoutcausinggenemutations, unscheduled
DNAsynthesis, sisterchromatidexchanges, orstructural chro-
mosomeaberrations (83,84). Thus, DEScaninducecelltrans-
formation intheabsenceofdetectable DNAdamage. However,
under these conditions, DES does induce one type ofgenetic
change, aneuploidy. Diethylstilbestrol binds tomicrotubulesand
disruptstubulinassembly(85-87). Treatmentofcellsinmitosis
withdosesaslowas 10nMDESresultsinaneuploidyinduction
via nondisjunction (83). Several lines ofevidence support the
hypothesis that aneuploidy is involved in DES-induced cell
transformation (88) andincludethefollowingfindings: a) DES
induces significantlevelsoflossorgainofone ortwochromo-
somes at nontoxic doses; b) DES induces aneuploidy and cell
transformation with parallel dose-response curves; c) aneu-
ploidy induction correlates with the ability to induce cell
transformationbyDES-relatedcompounds; d)cell-cyclespeci-
ficityofaneuploidyinductionandcelltransformationbyDES in-
dicate that cells in the G2/M phase are most sensitive; e) neo-
plastichamstercelllinesinducedbyDESarenear-diploidwith
a nonrandom chromosome change (trisomy 11); andJ) DES
disruptsmicrotubuleorganizationincells, providingabiochemi-
cal mechanism for induction ofchromosome nondisjunction.
In conclusion, it is clear that hormones can affect carcino-
genesisbyepigeneticmechanismssuchasstimulationofcellpro-
liferation ofestrogen-dependenttargetcellsandreprogramming
ofcellulardifferentiation. Inaddition, significantevidence ex-
ists that certain estrogens can also causegenetic alterations by
mechanismsnotinvolvingtheclassical estrogenreceptor. These
findings indicatethathormonalcarcinogenesis is mostlikely a
resultoftheinterplay ofbothgenetic andepigenetic factors.
Classification of Chemicals by
MechanismsofAction
The somatic mutation theory ofcarcinogenesis remains the
maintenetforexplainingthecarcinogenicactivityofchemicals
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Table 7. Possible explanations for nonmutagenic carcinogens
and mutagenic noncarcinogens.
Putative nonmutagenic carcinogens
Unusual metabolic activation is required for activity in mutational assays
(examples: amitrole and DES).
Mutagenic activity ofchemical is limited tochromosomal level, i.e., struc-
tural or numerical chromosome changes (examples: benzene, arsenicals,
DES, and asbestos).
Chemicals are inhibitors ofDNA methylation (examples: 5-azacytidine
and ethionine).
Chemicals act as tumor promoters (examples: phenobarbital, 2,3,7,8-tetra-
chlorodibenzo-p-dioxin, hormones, andasbestos).
Mutagenic noncarcinogens
Mutagenicity exhibited in test system may notbe exhibited in vivo due, for
example, todifferences in metabolic activation/detoxification or DNA
repair.
Mutagenicity ofachemical maybelimitedtoaparticulartypeofgeneticchange
(e.g., aneuploidy); becausecarcinogenesis requiresmultiplegeneticevents
ofdiverse types, a particular chemical mutagen may affect only a single
step in the carcinogenesis process.
Mutagenicity per se is not sufficient forcarcinogenicity due to lackofpro-
liferation in the target tissue.
Less-than-lifetime carcinogenicity studies may be too short to detect late-
appearing tumors.
In vivo rodent models are insensitive to weak mutagens.
DES, diethylstilbestrol.
(89). Some carcinogenic chemicals, however, apparently failto
elicit positive responses in in vitro assays for genetic toxicity.
Several possiblemechanismsorexplanations fortheseputative
nonmutagenic carcinogens can be proposed (Table 7).
Aproblem thatexists inmostin vitroassays isthenecessity for
exogeneous metabolic activation, and the lack of a positive
response inamutation assay mayrelatetothisrequirement. Even
thoughconsiderable advanceshavebeenmadeinthisareainthe
last several years, chemicals with unusual metabolic activation
pathways will undoubtedly bediscovered. Amitroleand DES are
possible examples.
Amitrole, a widely used herbicide, is an animal carcinogen
andan inducerofcell transformation (90,91). However, itisin-
active as a mutagen in bacterial test systems (90). Thus, it has
been suggested thatamitrole isanonmutagenic carcinogen. Over
the dose range that induced morphological transformation of
Syrian hamster embryo cells in culture, amitrole inducedgene
mutations atthe Na7/K+ ATPase andhypoxanthine phosphori-
bosyl transferase loci measuredconc,omitantly inthe samecells
(91). These findings indicate thatamitrole may act via a muta-
tional mechanismand contrastwith thenegative resultsobserved
with bacterial and other mutation assays. Although avariety of
mechanisms may account for differences in bacterial versus
mammalian cell mutagenesis, the most likely explanation is the
necessity for metabolism ofamitrole for its activity. SHE cells
are able to metabolize a variety ofchemical carcinogens to ac-
tive mutagens andtransforming intermediates (92). Kraus etal.
(93) have shown that amitrole is metabolized to mutagenic in-
termediates by peroxidases, including prostaglandin synthetase,
which is found inhigh levels in SHEcells, andlactoperoxidase,
amodel forthyroidperoxidase. Becausethethyroid isthetarget
organ for this carcinogen, these findings suggest that organ-
specific metabolism is important in amitrole carcinogenicity.
Many genotoxicity assays measure only the activity of a
chemical toinducepointmutations orDNAdamage. However,
chemicals canalso inducegenetic changes atthechromosomal
levelwithoutcausinggenemutationsordirectlydamagingDNA
(89,94). Thesechemicals, therefore, wouldbenegativeinsome
genotoxicity assays. Certain exceptions to the correlation bet-
ween carcinogenesis and mutagenicity based on results in the
Amestest(e.g., benzene, arsenic, DES, andasbestos) may relate
totheabilityofcertainchemicalstoactspecifically aschromo-
some mutagens (i.e., clastogens and/or aneuploidogens). The
data supporting the conclusion that DES and asbestos are
chromosomemutagenshavealready beendiscussed. Benzene,
a known human carcinogen, has been reported as negative in
mostgenemutationassays, butsomepositive resultshavebeen
presented (95-97). However, clearevidenceexiststhatcytogen-
etic damage is induced by benzene (63), indicating that it is
primarily aninducerofchromosomedamage, andthis is likely
itsmajormechanismofaction. Similarly, arsenicandarsenical
compounds areknownhumancarcinogens, which are inactive
orweakgenemutagens, butverypotentclastogens (63). Sodium
arsenite andsodiumarsenate induce morphological transforma-
tionofSHEcells inculture (98). Undertheseconditions, gene
mutations attwo genetic loci cannot be detected, but chromo-
someaberrations andgeneamplification (48) aresignificantly
increased, with a similardose response tothat forinduction of
celltransformation. Itislikely thatthere areotherexamples of
carcinogens thatareprimarily chromosome mutagens.
MethylationofDNAattheC-5positionofcytosineisimpor-
tant in the regulation of gene expression and is one possible
epigenetic mechanism for the heritable change in cancer cells
(99). Chemicals suchas5-azacytidine andethionine mayeffect
DNAmethylationthroughaninteractionwiththeDNAmethyl-
transferase enzyme. It has also been suggested that DNA-
alkylatingagents mayheritablyalterDNAmethylationpatterns
(99). Thisprovidesanepigeneticmechanism forheritablealtera-
tions in expression ofgenes involvedin carcinogenesis.
Otherepigenetic mechanisms forcarcinogenscanbeproposed
(1). Anumberofthesemayinvolvethetumor-promotingactivity
of the carcinogenic chemical. It is imperative, however, to
rememberthatgenetic andepigeneticmechanisms forachemi-
calarenotmutuallyexclusive. Manyofthechemicals shownto
have genetic activity also display epigenetic properties and
tumor-promoting activity, which areundoubtedly important in
theircarcinogenicpotential. Thethyroidhormonedisturbances
causedbyamitrole (90)andthepossibletargetorganmutagenici-
tyofthischemical arebothpotential mechanismsthatpossibly
play dual roles inits carcinogenicity. Similarly, DES andother
hormonal carcinogens may operate through multiple mecha-
nisms as discussed earlier.
Weisburger andWilliams (100) haveproposed classification
ofchemicalcarcinogens onthebasisofmechanismofactioninto
two groups: genotoxicandepigenetic. Twoproblemsexistwith
thisclassification: first, theterminology isproblematic, andse-
cond, classification impliesexclusivity, which isprobablyrarely
thecasewithachemicalcarcinogen. Thetermgenotoxic [which
has now been replaced (101) with "DNA reactive" due to the
confusion with the original usage ofthe word by Druckrey] is
usedtodescribespecificallycarcinogensthatundergochemical
reactionwith DNA. CarcinogensthatarenotDNAreactivebut
display other properties that could underlie an increase in
neoplasms (for example, promoting activity), are termed
"epigeneticcarcinogens" (100). Unfortunately, thisdefinitionof
epigenetic carcinogen describes the observed action of the
15J. C. B4RRETT
Table 8 Mechanisms ofchemically induced mutations in tumors.
Chemical - DNA (adduct) - mutation
Chemical - microtubule (spindle dysfunction) - DNA (aneuploidy) - mutation
Chemical- 02 (activated) - DNA - mutation
Chemical - receptor - enzyme - 02 (activated) - DNA - mutation
Chemical - receptor - protein (e.g., recombinase) - DNA - mutation
Chemical - receptor - protein - DNA synthesis/cell division (normal) - mutation
Chemical - receptor - protein - DNA synthesis/cell division (abnormal, i.e., mutation rate) - mutation
Chemical - receptor - protein - DNA synthesis/cell division - tumor - mutation
chemical ratherthan themechanismofthealteration incellular
phenotype, which is the original context in which this term is
used (8). This cancreateconsiderableconfusion. Forexample,
chemicals thatdo not reactdirectly with DNA, suchas spindle
poisons or generators ofoxygen radicals, but through indirect
mechanisms resultingeneticchangessuchaschromosomerear-
rangementoraneuploidy, wouldbecalledepigeneticcarcinogens
byWilliams andWeisburger's terminology. Itisanonsequiturto
call achemicalthatinducesageneticchangeanepigeneticchem-
ical. Likewise, DNA-reactivechemicals (forexample, methylat-
ing agents) may causeheritable, epigenetic cellularchangesby
altering DNAmethylation (99) orgeneexpression(102). Should
thesechemicalsbecalledgenotoxic orepigenetic?Accordingto
Williams and Weisburger's classification, they are genotoxic,
while their mechanism of action may involve an epigenetic
change.
Most, ifnotall, tumors havegenetic changes, which may or
may not result frommutagenic exposures. Itisuseful tounder-
standthemechanismsbywhichcarcinogenic chemicals induce
genetic changesthatariseinchemically induced tumors. Rather
than simply dividing the possible mechanisms into two cate-
gories, i.e., genotoxic andnongenotoxic, anumberofmechan-
isms of chemically induced mutations in tumors can be envi-
sioned(Table 8). Ifachemical inducesacancerandthatcancer
has genetic changes, itispossiblethatthechemicaldirectly in-
ducedthegeneticchange, forexample, duetoaDNAadduct. At
another extreme, the chemical may induce the cancer by a
nongenetic mechanism, thetumorbecomesgeneticallyunstable
andmutationsariseduetothenatureofthetumorratherthanthe
mutation causing thetumor. Anumberofmechanisms existbe-
tweenthesetwoextremes. Thechemical may inducemutations
by indirect mutational mechanisms, e.g., disruption ofspindle
function orgenerationofreactive oxygen radicals. Thesereac-
tiveoxygen radicals mayariseduetotheintrinsicproperties of
thechemical orduetoreceptor-mediatedproductionofenzymes
increasing ratesofoxygenmetabolismincells. Otherreceptor-
mediated changes can indirectly lead to mutations as well, as
outlined inTable8. Anyattempttoclassifychemicalcarcinogens
by mechanismofmutationinduction mustconsiderthecomplex-
ity and the multitude ofpossible mechanisms.
Many chemical carcinogens operate via a combination of
mechanisms, andeventheirprimary mechanismofactionmay
varydepending onthetargetcells. Forexample, somechemicals
arecompletecarcinogensinonetissue,promotersinanother,and
initiatorsinanother.Classificationofchemicalsintoasinglecate-
gory may bemisleading andhinder ourcomprehensive under-
standingofthecomplexproblemofchemicalcarcinogenesis.
The need to understand the mechanism(s) ofchemical car-
cinogens isclearlyevident. However, theexerciseofclassifying
chemicals accordingtomechanismhascertaininherentdifficul-
ties. AworkinggroupofIARCconcludedthatnoclassification
ofchemicals according to mechanisms could be exhaustive or
definitive(103). Thisconclusionis still supportedbyourcurrent
understandingofthemolecularbasisofmultistepcarcinogenesis.
Onepossibleadvantageofclassificationofcertainchemicals
istodistinguishchemicals withdifferentdose-responsecharac-
teristics, inparticularchemicals forwhich athresholdmay ex-
ist. This is an area aboutwhich too little is currently known to
draw any conclusions. Itisthisauthor'sopinion thatchemicals
exhibiting athresholddoseresponsemaybeidentified, butthis
response will be related to the individual characteristics of a
given chemical and not to its characteristic biological activity.
Both mutagenic and nonmutagenic chemicals may exhibit
thresholds, andlikewisechemicalsmayexertepigeneticeffects
with a lineardose response. Therefore, no generalizations can
bemade, andeachchemical will requireindependentanalysis.
Role ofCell Proliferation in
Carcinogenesis
Cell proliferation can influence carcinogenesis by a number
ofmechanisms (Table9). Thishasledtothehypothesisthatcell
proliferationpersemaybecarcinogenicandcarcinogensthatin-
crease cell proliferation may be operating exclusively by this
mechanism. Thefailuretodetectameasurablemutagenicactivi-
tyassociatedwithnongenotoxiccarcinogens indicatesthatthese
chemicals may actbyalternative mechanisms ofaction, increas-
ing cell proliferation being one possibility. This hypothesis is
supportedbythefactthatmost, ifnotall, typesofcancers may
arise spontaneously in atleast some species. Normal cell divi-
sion results in a low level of spontaneous errors during DNA
replication, and spontaneous DNA damage can result from
cytosine deamination at physiological temperatures, from ox-
idativedamageassociatedwithnormalcellularphysiology, and
frommutagens infood, air, orwater(104). Thus, mutationsoc-
cur "spontaneously" fromnormalcellularprocesses. There are
risk factors for human cancers (e.g., hormones) that also in-
fluence the rate ofcellproliferation intargettissue (73). How-
ever, mechanisms inadditiontocellproliferation shouldbecon-
sidered for these risk factors (videsupra).
Table9.Mechanismsbywhichchemicalsaffectingcellproliferationmight
influencecarcinogenesis.
Increase fixation andexpressionofpremutagenic DNA lesions
Increase the number of initiated cells occurring spontaneously during cell
replication
Increase the number of spontaneous initiated cells by blocking cell death/
elimination
Increase the number of initiated cells by perturbing checkpoints in the cell
cycle leading to mutagenic events
Increase the rateofneoplastic progression by previous four mechanisms
Promoteclonal expansionofinitiated cells
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Table 10. Evidence against cell proliferation per se being carcinogenic.
Many toxic and/or hyperplastic stimuli are noncarcinogenic.
Cell division occurs frequently in all organismsa
For humans:
I egg - 10'4 cells in adultorganism
10i3 cells still capable ofcell division
107 cell divisions/sec occur in adult organism
10 cell divisions/sec in intestine
Multiple mutations (3-4?) are required foranormal cell toevolve intoacancer
cell.
'D. Prescott, personal communications.
Beforecellproliferationpersecanbeacceptedasthecausative
mechanismforcertaincarcinogens, several facts shouldbecon-
sidered (Table 10). First, many toxic and/orhyperplastic stimuli
are notcarcinogenic (105-108). A reviewoftheliterature inthis
field and further studies ofnoncarcinogenic, toxic agents are
needed. Second, celldivision occurs frequently inallorganisms
(Table 10); therefore, it is not clear whether cell division is
limiting inthecarcinogenicprocess. This, ofcourse, dependson
the target tissue. Furthermore, cell division ofinitiated or in-
termediate cells may occuratquitedifferent ratesthandivision
ofnormalcells. Finally, theobservationthatmultiplemutations
are involvedinthedevelopmentofmanyneoplasmsmay suggest
thateven aweakmutagenic response, whichisbelowthelevelof
detection ofcurrent assays, is sufficient to influence the neo-
plastic process ina specific targettissue. This isaplausible ex-
planation forcertain nongenotoxic carcinogens, someofwhich
may act by indirect mutagenic processes.
Summary
Mutational mechanisms canbeproposed formost, ifnotall,
known human carcinogens. Many ofthese chemicals are elec-
trophilicormetabolicallyactivatedtoreactivemoleculesthatcan
alter DNA, causinggenetic damageanddifferenttypesofmuta-
tions. Evensomepreviouslyproposednongenotoxichumancar-
cinogens (e.g., hormonesandasbestos)exhibitmutationalactivi-
ty when assays for chromosomal mutations are used. Because
thesechemicals areusually inactiveintheSalmonellaassayand
othergenemutation assays, moreemphasishasbeenplaced on
their nonmutational mechanisms. Clear evidence exists that
these carcinogens can alter gene expression and stimulate cell
proliferationbyepigeneticmechanisms. Thesepropertiesareun-
doubtedly important in the carcinogenic activity of these
chemicals. Although lesswell studied, DNA-reactive, genotoxic
carcinogensalsoaltergeneexpressionandincreasecellturnover
by epigenetic mechanisms.
These findings areconsistentwiththecurrentunderstanding
of the molecular basis ofmultistep carcinogenesis. The neo-
plastic evolutionofmostcommonhumancancersoccurs asthe
result of multiple mutational events. The molecular basis for
thesemutations isvariedandincludespointmutations, deletion
mutations, chromosome rearrangements, gene amplification,
and chromosome losses and gains. Therefore, different muta-
tional activities ofcarcinogens can influence the carcinogenic
process at different steps. In addition, chemical influences on
geneexpressionandcellproliferationareimportantinallowing
clonal expansionofpreneoplasticcellsandindisruptingthesup-
pressive effects ofsurrounding normal cells on preneoplastic
cells (109).
The mechanisms ofaction ofhuman carcinogens, and likely
many rodent carcinogens, will include both genetic and epi-
genetic processes. Carcinogenesis is a multistep, multigenic,
multicausal process (8). As such, both epigenetic and genetic
factors are probably important. Thus, it should notbe surpris-
ing thatchemicals thatarecarcinogenic oftenhavetheability to
inducebothtypesofchanges. Thesemechanisms arenotmutual-
lyexclusive; rather, theyprobably workinconjunction toresult
in neoplastic progression.
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